BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...
The Chosun Ilbo on MSN
K-Bio stocks surge 80%: Will rally continue in 2025?
Seers Technology, D&D Pharmatech, OliX, ABL Bio. Among the top 10 stocks by share price growth this year, four were ...
National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...
Yarilet Perez is an experienced multimedia journalist and fact-checker with a Master of Science in Journalism. She has worked in multiple cities covering breaking news, politics, education, and more.
Objectives The use of economic evidence to prioritise vaccines and delivery strategies to optimally use in immunisation systems is becoming a global priority, especially in low- and middle-income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results